Dr. Lee, Te-Chang 李德章 博士

Brand

Dr. Lee, Te-Chang
李德章 博士

Distinguished Research Fellow
特聘研究員

Specialty:
  • Genetic and Molecular Toxicology
  • Cancer Biology
  • Pharmacology

RESEARCH

The long-term goals of my laboratory are: (1) to understand the mechanisms underlying which sustained arsenic stress reprograms the gene expression via epigenetic alterations; (2) to explore the therapeutic application of inorganic arsenic; and (3) to investigate and develop novel anticancer drugs. Chronic exposure to inorganic arsenic (iAs) continues to be a severe toxicological and pathological problem in humans. During the past decade, we focused on the gene reprogram in cells under sustained genotoxic stress by iAs and several novel genes were shown to have oncogenic potential. Our recent studies have shown that long-term exposure of cells to iAs induces changes of DNA methylation and chromatin structure, hence results in gene expression profile change and malignant transformation. Arsenic trioxide (ATO) has been approved as effective drug against refractory acute promyelocytic leukemia. Since ATO also inhibits DNA repair, we are further investigated its application strategy for treatment of other solid tumors. Via collaboration with Dr. T. L. Su, a medicinal chemist in IBMS, we have demonstrated that several newly synthesized bifunctional alkylating agents are potent anticancer agents. Some of them were even able to overcome the MDR cancer cells.

研究介紹

本研究室的長期目標為:

(1) 瞭解長期砷暴露經表觀遺傳調控基因表現之機制

(2) 探討無機砷之抗癌活性

(3) 研發新穎抗癌藥物。

 

無機砷長期暴露仍為嚴重的人們毒理及病理問題;過去數年來我們探討長期砷暴露誘引之基因表現改變,並評估具有致癌活性的新穎性基因。最近的成果發現 ,無機砷長期暴露可改變DNA甲基化及染色體結構而造成基因表現變異及細胞癌化。三氧化二砷(ATO)的抗癌已是治療急性前骨髓白血病的有效藥物,由於ATO具有抑制DNA修復的能力,我們進一步探討其應用在治療其他腫瘤策略。經與本所醫藥化學家蘇燦隆博士之合作,近年來我們驗證許多新合成雙官能烷化劑的抗癌活性,部分化合物甚具抑制多重抗藥性癌細胞之活性。

HIGHLIGHT 重要成果

MORE 更多

CREW PHOTO 成員合照

團體照
Top